EUVIMEDEUVIMED entdecken
Open Access

HIV incidence in US first‐time blood donors during 12 and 3 month deferral policy periods between 2015 and 2023 before implementation of individual donor assessment

Eduard Grebe iD, Clara Di Germanio iD, Edward P Notari, Mars Stone, Jahnavi Reddy Bhaskar, Venkata Dayana, Marion C Lanteri iD, Jed Gorlin, Rita Reik, Susan L Stramer, Michael P Busch, Benyam Hailu und 5 weitere

Transfusion · 2025

DOI: 10.1111/trf.18195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2025. Verfasst von Eduard Grebe und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vitalant Research Institute, San Francisco, California, USA. Hauptthemen laut MEDLINE: HIV Infections, Blood Donors, Donor Selection. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: U.S. Department of Health and Human Services, FDA HHS, National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Following FDA guidance, US blood collectors changed donor deferral for men who have sex with men (MSM) from indefinite to a 12 month deferral in 2016 (12 m), and for MSM and several other exposure risks to 3 month deferrals in 2020 (3 m). We evaluated first‐time donor (FTD) HIV incidence and demographics during these periods. Study Design and Methods We estimated cross‐sectional HIV incidence and incidence rate differences in FTD based on routine donation nucleic acid testing (NAT) and serology with additional limiting antigen (LAg)‐Avidity immunoassay and viral load testing. We estimated incidence in the two policy periods (12 and 3 m), incidence trends in two‐year intervals between 2015 and 2023, and used multivariable Poisson regression to assess demographic correlates of incident infection.

Results

HIV incidence in FTD during the 12 m deferral period was 2.82 infections/10 5 person‐years (PY) [95% CI: 2.12, 3.67] and during the 3 m deferral period, it was 1.88/10 5 PY (95% CI: 1.18, 2.67), a statistically significant decline ( p < .05). Over the period 2015–2023, incidence was stable. Male sex, younger age, Black or African American race, Hispanic ethnicity, and residence in the South were associated with incident infection in regression analysis, but the time‐based deferral policy periods were not.

Discussion

HIV incidence in FTD did not increase between 2015 and 2023. An overall decline in HIV incidence in the 3 m deferral period compared with the 12 m deferral period was evident. These results provide no indication of an increased residual risk of transfusion‐transmitted HIV from FTD in the United States with the reduced deferral periods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsBlood DonorsDonor SelectionHumansMaleIncidenceAdultUnited StatesMiddle AgedFemaleCross-Sectional StudiesHomosexuality, MaleYoung Adult

Stichwörter der Autor:innen

HIVtransfusion‐transmitted disease

Autor:innen und Institutionen

  • Vitalant Research Institute, San Francisco, California, USA.
  • American Red Cross, Rockville, Maryland, USA.
  • University of California San Francisco, San Francisco, California, USA.
  • Creative Testing Solutions, Tempe, Arizona, USA.
  • New York Blood Center Enterprises, New York, New York, USA.
  • OneBlood, St Petersburg, Florida, USA.

ORCID-Profile: Eduard Grebe, Clara Di Germanio, Marion C Lanteri, Artur A Belov, Barbee Whitaker, Brian Custer

Förderung

  • U.S. Department of Health and Human Services
  • FDA HHS
  • National Institutes of Health (NIH)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • U.S. Food and Drug Administration

Zitieren

APA

Grebe, E., Di Germanio, C., Notari, E. P., Stone, M., Bhaskar, J. R., Dayana, V., Lanteri, M. C., Gorlin, J., Reik, R., Stramer, S. L., Busch, M. P., Hailu, B., Belov, A. A., Yang, H., Whitaker, B., Custer, B., & US Transfusion‐Transmissible Infections Monitoring System (TTIMS) (2025). HIV incidence in US first‐time blood donors during 12 and 3 month deferral policy periods between 2015 and 2023 before implementation of individual donor assessment. Transfusion. https://doi.org/10.1111/trf.18195

Vancouver

Grebe E, Di Germanio C, Notari EP, Stone M, Bhaskar JR, Dayana V, et al. HIV incidence in US first‐time blood donors during 12 and 3 month deferral policy periods between 2015 and 2023 before implementation of individual donor assessment. Transfusion. 2025. doi:10.1111/trf.18195

BibTeX
@article{Grebe2025,
  author = {Grebe, Eduard and Di Germanio, Clara and Notari, Edward P and Stone, Mars and Bhaskar, Jahnavi Reddy and Dayana, Venkata and Lanteri, Marion C and Gorlin, Jed and Reik, Rita and Stramer, Susan L and Busch, Michael P and Hailu, Benyam and Belov, Artur A and Yang, Hong and Whitaker, Barbee and Custer, Brian and US Transfusion‐Transmissible Infections Monitoring System (TTIMS), US Transfusion‐Transmissible Infections Monitoring System (TTIMS)},
  title = {HIV incidence in US first‐time blood donors during 12 and 3 month deferral policy periods between 2015 and 2023 before implementation of individual donor assessment},
  journal = {Transfusion},
  year = {2025},
  doi = {10.1111/trf.18195}
}
Kostenlos starten →